- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05401279
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
15 août 2022 mis à jour par: RenJi Hospital
Bladder Sparing Treatment of Tislelizumab Combined With Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer (T2-3N0M0): a Phase II Prospective Study
This is a phase II open label single-arm prospective study aiming to investigate the efficacy of PD-1 inhibitor Tislelizumab combined with conventional gemcitabine and cisplatin as bladder sparing treatment for patients with PD-L1 positive muscle invasive bladder carcinoma (T2-3N0M0).
Aperçu de l'étude
Statut
Recrutement
Les conditions
Intervention / Traitement
Description détaillée
The study will enroll 20 patients with adequate organ function and performance status who either wish to attempt bladder preserving therapy or are ineligible for radical cystectomy.
The bladder samples must be available and assessed as positive for PD-L1 expression .
Patients will receive transurethral resection or partial cystectomy to remove all visible tumors with no residual disease left.
After the surgery, patients will receive 8 cycles of tislelizumab combined with 4-6 cycles of gemcitabine and cisplatin.
Type d'étude
Interventionnel
Inscription (Anticipé)
20
Phase
- Phase 2
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Yunze Xu, PhD
- Numéro de téléphone: +8618801967501
- E-mail: rjxuyunze@163.com
Lieux d'étude
-
-
Shanghai
-
Shanghai, Shanghai, Chine, 200127
- Recrutement
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University
-
Contact:
- Yunze Xu, PhD
- Numéro de téléphone: +8618801967501
- E-mail: rjxuyunze@163.com
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 75 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Histologically confirmed muscle-invasive urothelial cancer of the bladder within 60 days of study enrollment. Variant histology and cis are not allowed. Patients must be willing to provide a TURBT specimen during screening and prior to enrollment if adequate specimen (FFPE tissue block or 20 unstained slides) from initial TURBT documenting muscle-invasive urothelial bladder cancer is not available. The specimen must be assessed as PD-L1 positive by two pathologists using SP263 kit.
- Clinical stage T2-T3, N0, M0 urothelial bladder cancer.
- Deemed to not be a candidate for radical cystectomy by attending urologic oncologist or refuse radical cystectomy.
- Willing to receive maximal transurethral resection or partial cystectomy to remove all bladder tumors
- Be willing and able to provide written informed consent/assent for the trial.
- Have a performance status of 0 or 2 on the Eastern Cooperative Oncology Group Performance Scale.
Demonstrate adequate organ function as defined below, all screening labs should be performed within 10 days of protocol enrollment.
- Absolute neutrophil count >= 1,500 /mcL;
- Platelets >= 100,000 /mcL;
- Hemoglobin >= 9.0 g/dL;
- Serum creatinine <=1.5 x upper limit of normal (ULN) or calculated creatinine clearance >= 30 mL/min as calculated by Cockcrof-Gault formulae or by 24 hour urine collection;
- Serum total bilirubin <=1.5 x ULN or direct bilirubin <= ULN for subjects with total -bilirubin levels > 1.5 x ULN;
- Aspartate aminotransferase and alanine aminotransferase <= 1.5 x ULN;
- Albumin >= 2.5 mg/dL;
- International normalized ratio or prothrombin time (PT) <= 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or partial prothrombin time (PTT) is within therapeutic range of intended use of anticoagulants;
- Activated Partial Thromboplastin Time (aPTT) <= 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
- Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
Exclusion Criteria:
- Has received prior radiation therapy or systemic chemotherapy for urothelial bladder cancer including neoadjuvant chemotherapy. Prior intravesical chemotherapy or intravesical immunotherapy is permissible, however, no prior intravesical therapy is permitted within 4 weeks of study enrollment; adjuvant therapy is not permitted.
- Has received prior pelvic radiation therapy.
- Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Has a known history of active TB (Bacillus Tuberculosis).
- Hypersensitivity to tislelizumab or any of its excipients.
- Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- Any prior history of invasive malignancy within the past 5 years except non-melanoma skin cancer, carcinoma in-situ, localized prostate cancer without biochemical recurrence following definitive treatment.
- Has other active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- History of Guillain-Barre Syndrome or Stevens-Johnson Syndrome
- Has known history of, or any evidence of active, non-infectious pneumonitis.
- Has an active infection requiring systemic therapy.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- Has received a live vaccine within 30 days of planned start of study therapy. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Gemcitabine, Cisplatin and Tislelizumab
Patients will receive transurethral resection or partial cystectomy to remove all visible tumors with no residual disease left.
2-4 weeks after the surgery, patients will receive 8 cycles of tislelizumab combined with 4-6 cycles of gemcitabine and cisplatin.
|
Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.
Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four to six 21-day cycles.
Cisplatin 70mg^m2 will be administered on Day 1 for four to six 21-day cycles.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Taux de survie sans maladie à deux ans avec une vessie intacte
Délai: 2 années
|
La survie sans maladie de la vessie intacte est définie comme le temps écoulé entre le début du protocole thérapeutique et le développement d'une récidive de cancer de la vessie envahissant les muscles, d'une récidive pelvienne régionale, de métastases à distance, d'un décès lié au cancer de la vessie ou d'une cystectomie.
|
2 années
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse Events
Délai: 2 years
|
The adverse events are evaluated per Common Terminology Criteria for Adverse Events (CTCAE) 5.
|
2 years
|
|
Overall survival
Délai: up to 5 years
|
Defined as time to death from beginning of protocol therapy
|
up to 5 years
|
|
Survie sans métastase
Délai: jusqu'à 5 ans
|
Défini comme le temps jusqu'au développement de métastases radiographiques à distance depuis le début du protocole thérapeutique.
|
jusqu'à 5 ans
|
|
Disease-free survival
Délai: up to 5 years
|
Defined as time to recurrence, metastasis or death from beginning of protocol therapy.
|
up to 5 years
|
|
Disease specific survival
Délai: up to 5 years
|
Defined as time to death because of bladder cancer from beginning of protocol therapy
|
up to 5 years
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Wei Xue, PhD, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 juin 2022
Achèvement primaire (Anticipé)
1 avril 2024
Achèvement de l'étude (Anticipé)
1 mai 2025
Dates d'inscription aux études
Première soumission
29 mai 2022
Première soumission répondant aux critères de contrôle qualité
29 mai 2022
Première publication (Réel)
2 juin 2022
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
18 août 2022
Dernière mise à jour soumise répondant aux critères de contrôle qualité
15 août 2022
Dernière vérification
1 août 2022
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs
- Tumeurs urologiques
- Tumeurs urogénitales
- Tumeurs par site
- Maladies urologiques
- Maladies de la vessie urinaire
- Tumeurs de la vessie urinaire
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Agents antiviraux
- Inhibiteurs d'enzymes
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Gemcitabine
Autres numéros d'identification d'étude
- TICIG
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Non
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .